I-Mab (NASDAQ:NBP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of I-Mab (NASDAQ:NBP) from a hold rating to a buy rating in a research report released on Saturday morning.

Several other analysts have also recently commented on the company. HC Wainwright raised their target price on I-Mab from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings started coverage on I-Mab in a research note on Thursday. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

I-Mab Stock Performance

I-Mab stock opened at $3.47 on Friday. I-Mab has a fifty-two week low of $0.60 and a fifty-two week high of $6.79.

I-Mab (NASDAQ:NBP) last posted its quarterly earnings data on Thursday, December 18th. The company reported ($0.07) EPS for the quarter.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.